Anna Skwarska

6.7k total citations
31 papers, 337 citations indexed

About

Anna Skwarska is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Anna Skwarska has authored 31 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 10 papers in Hematology and 8 papers in Oncology. Recurrent topics in Anna Skwarska's work include Acute Myeloid Leukemia Research (8 papers), Protein Degradation and Inhibitors (8 papers) and Cancer therapeutics and mechanisms (8 papers). Anna Skwarska is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Protein Degradation and Inhibitors (8 papers) and Cancer therapeutics and mechanisms (8 papers). Anna Skwarska collaborates with scholars based in Poland, United States and United Kingdom. Anna Skwarska's co-authors include Ewa Augustin, Jerzy Konopa, Ester M. Hammond, Ewen D. D. Calder, Justyna Kucińska‐Lipka, Stuart J. Conway, I. Gubańska, Marina Konopleva, Magdalena Niemira and Jacek M. Witkowski and has published in prestigious journals such as Blood, Cancer Research and Scientific Reports.

In The Last Decade

Anna Skwarska

28 papers receiving 335 citations

Peers

Anna Skwarska
Xiuhua Wu China
Chao Feng China
Daiju Ichikawa Japan
Wenbin Kuang China
Yijun Cao China
Amanda E. Brinker United States
Jorge Luis María Ruiz Brazil
Joseph F. Pizzolato United States
Takashi Yaegashi Japan
Seong‐Min Kwon South Korea
Xiuhua Wu China
Anna Skwarska
Citations per year, relative to Anna Skwarska Anna Skwarska (= 1×) peers Xiuhua Wu

Countries citing papers authored by Anna Skwarska

Since Specialization
Citations

This map shows the geographic impact of Anna Skwarska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Skwarska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Skwarska more than expected).

Fields of papers citing papers by Anna Skwarska

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Skwarska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Skwarska. The network helps show where Anna Skwarska may publish in the future.

Co-authorship network of co-authors of Anna Skwarska

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Skwarska. A scholar is included among the top collaborators of Anna Skwarska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Skwarska. Anna Skwarska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chwiałkowska, Karolina, A. Zeller, Anna Skwarska, et al.. (2025). Repurposing of PI3K inhibitors for high-grade serous ovarian cancer: A novel competing endogenous network analysis-based approach. Computers in Biology and Medicine. 194. 110471–110471.
2.
3.
Skwarska, Anna & Marina Konopleva. (2023). BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs. Cancer Research. 83(21). 3501–3503. 11 indexed citations
4.
Bielska, Agnieszka, Anna Skwarska, Adam Krętowski, & Magdalena Niemira. (2022). The Role of Androgen Receptor and microRNA Interactions in Androgen-Dependent Diseases. International Journal of Molecular Sciences. 23(3). 1553–1553. 11 indexed citations
5.
Bielska, Agnieszka, Magdalena Niemira, Witold Bauer, et al.. (2022). Serum miRNA Profile in Diabetic Patients With Ischemic Heart Disease as a Promising Non-Invasive Biomarker. Frontiers in Endocrinology. 13. 888948–888948. 14 indexed citations
6.
Calder, Ewen D. D., et al.. (2021). Zap‐Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat. ChemMedChem. 16(24). 3691–3700. 9 indexed citations
7.
Skwarska, Anna, Ewen D. D. Calder, Ishna N. Mistry, et al.. (2021). Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. Cell chemical biology. 28(9). 1258–1270.e13. 28 indexed citations
8.
9.
Calder, Ewen D. D., Anna Skwarska, Lisa K. Folkes, et al.. (2020). Hypoxia-activated pro-drugs of the KDAC inhibitor vorinostat (SAHA). Tetrahedron. 76(21). 131170–131170. 17 indexed citations
10.
Bowler, Elizabeth, Anna Skwarska, Joseph D. Wilson, et al.. (2020). Pharmacological Inhibition of ATR Can Block Autophagy through an ATR-Independent Mechanism. iScience. 23(11). 101668–101668. 8 indexed citations
11.
Niemira, Magdalena, Adrianna Moszyńska, Marcin Ratajewski, et al.. (2020). Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells. Biomedicines. 8(9). 292–292. 6 indexed citations
12.
Zalewska-Piątek, Beata, Marcin Olszewski, Tomasz Lipniacki, et al.. (2020). A shear stress micromodel of urinary tract infection by the Escherichia coli producing Dr adhesin. PLoS Pathogens. 16(1). e1008247–e1008247. 20 indexed citations
13.
Augustin, Ewa, et al.. (2015). The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells. Acta Pharmacologica Sinica. 36(3). 385–399. 6 indexed citations
14.
Skwarska, Anna, et al.. (2015). Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells. Biochemical Pharmacology. 95(4). 238–252. 10 indexed citations
15.
Skwarska, Anna, et al.. (2013). DNA-Damaging Imidazoacridinone C-1311 Induces Autophagy followed by Irreversible Growth Arrest and Senescence in Human Lung Cancer Cells. Journal of Pharmacology and Experimental Therapeutics. 346(3). 393–405. 27 indexed citations
16.
Wiśniewska, Anita, Magdalena Niemira, Karolina Jagiełło, et al.. (2012). Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells. Biochemical Pharmacology. 84(1). 30–42. 10 indexed citations
17.
Beffinger, Michał & Anna Skwarska. (2012). The Role of FLT3 Kinase as an AML Therapy Target. Current Pharmaceutical Design. 18(19). 2758–2765. 6 indexed citations
18.
Skwarska, Anna, et al.. (2011). Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis. Cancer Biology & Therapy. 12(7). 586–597. 20 indexed citations
19.
Skwarska, Anna, Ewa Augustin, & Jerzy Konopa. (2007). Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311. APOPTOSIS. 12(12). 2245–2257. 35 indexed citations
20.
Augustin, Ewa, et al.. (2006). Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. Biochemical Pharmacology. 72(12). 1668–1679. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiuhua Wu Breakdown of academic impact, for papers by Chao Feng Breakdown of academic impact, for papers by Daiju Ichikawa Breakdown of academic impact, for papers by Wenbin Kuang Breakdown of academic impact, for papers by Yijun Cao Breakdown of academic impact, for papers by Amanda E. Brinker Breakdown of academic impact, for papers by Jorge Luis María Ruiz Breakdown of academic impact, for papers by Joseph F. Pizzolato Breakdown of academic impact, for papers by Takashi Yaegashi Breakdown of academic impact, for papers by Seong‐Min Kwon
Rankless by CCL
2026